Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06990269
PHASE2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Sponsor: ADARx Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Official title: A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Key Details

Gender

All

Age Range

60 Years - Any

Study Type

INTERVENTIONAL

Enrollment

240

Start Date

2025-11-10

Completion Date

2027-12

Last Updated

2026-03-02

Healthy Volunteers

No

Interventions

DRUG

ADX-038

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Locations (17)

ADARx Clinical Site

Gilbert, Arizona, United States

ADARx Clinical Site

Phoenix, Arizona, United States

ADARx Clinical Site

Beverly Hills, California, United States

ADARx Clinical Site

Huntington Beach, California, United States

ADARx Clinical Site

Poway, California, United States

ADARx Clinical Site

Orlando, Florida, United States

ADARx Clinical Site

Hagerstown, Maryland, United States

ADARx Clinical Site

Erie, Pennsylvania, United States

ADARx Clinical Site

McAllen, Texas, United States

ADARx Clinical Site

Round Rock, Texas, United States

ADARx Clinical Site

San Antonio, Texas, United States

ADARx Clinical Site

The Woodlands, Texas, United States

ADARx Clinical Site

Albury, New South Wales, Australia

ADARx Clinical Site

Parramatta, New South Wales, Australia

ADARx Clinical Site

Rowville, Victoria, Australia

ADARx Clinical Site

Ottawa, Ontario, Canada

ADARx Clinical Site

Toronto, Ontario, Canada